

DAFTAR PUSTAKA

- Abbas Abul, Lichtman Andrew PS. Cellular and Molecular Immunology. Philadelphia: Elsevier Ltd; 2018. p. 8-18, 399-417
- Baras, A. S. *et al.* (2016) 'The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder', *OncoImmunology*, 5(5), pp. 1–7. doi: 10.1080/2162402X.2015.1134412.
- Bellmunt, J. *et al.* (2015) 'Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma', *Annals of Oncology*, 26(4), pp. 812–817. doi: 10.1093/annonc/mdv009.
- Bellmunt, J., Powles, T. and Vogelzang, N. J. (2017) 'A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now', *Cancer Treatment Reviews*, 54, pp. 58–67. doi: 10.1016/j.ctrv.2017.01.007.
- Biomarker, I. I. (2017) 'Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for ', (August). doi: 10.1097/PAP.000000000000162.
- Boorjian, S. A. *et al.* (2008) 'T-Cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival', *Clinical Cancer Research*, 14(15), pp. 4800–4808. doi: 10.1158/1078-0432.CCR-08-0731.
- Burger, M. *et al.* (2007) 'Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade', *British Journal of Cancer*, 96(11), pp. 1711–1715. doi: 10.1038/sj.bjc.6603784.
- Chandrasekar, M., Saranya V, S. V and Surekha B, S. B. (2020) 'Analysis of

- Clinicopathological Parameters and Ki 67 Immunoexpression in Urothelial Neoplasms of Bladder’, *Annals of Pathology and Laboratory Medicine*, 7(1), pp. A21-27. doi: 10.21276/apalm.2494.
- Compérat, E. M. *et al.* (2019) ‘Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”’, *European Urology Focus*, 5(3), pp. 457–466. doi: 10.1016/j.euf.2018.01.003.
- Dietrich, B. and Srinivas, S. (2018) ‘Urothelial carcinoma : the evolving landscape of immunotherapy for patients with advanced disease’, pp. 7–16.
- Han, Y., Liu, D. and Li, L. (2020) ‘PD-1/PD-L1 pathway: current researches in cancer.’, *American journal of cancer research*, 10(3), pp. 727–742. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/32266087>.
- Huang, H. S. *et al.* (2018) ‘Prognostic impact of tumor infiltrating lymphocytes on patients with metastatic urothelial carcinoma receiving platinum based chemotherapy’, *Scientific Reports*, 8(1), pp. 1–7. doi: 10.1038/s41598-018-25944-1.
- Huang, T.-H., Cheng, W. and Wang, Y.-H. (2021) ‘Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma’, *Diagnostics*, 11(3), p. 448. doi: 10.3390/diagnostics11030448.
- Huang, W. *et al.* (2019) ‘Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis’, *Breast Cancer Research and Treatment*, 178(1), pp. 17–33. doi: 10.1007/s10549-019-05371-0.
- Huang, Y. *et al.* (2015) ‘The prognostic significance of PD-L1 in bladder cancer’, *Oncology Reports*, 33(6), pp. 3075–3084. doi: 10.3892/or.2015.3933.
- Ikarashi, D. *et al.* (2020) ‘Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report’, *Frontiers in Oncology*,

10(September), pp. 1–6. doi: 10.3389/fonc.2020.564714.

Jang, M. H. *et al.* (2017) ‘A comparison of Ki-67 counting methods in luminal Breast Cancer : The Average Method vs . the Hot Spot Method’, pp. 1–15. doi: 10.1371/journal.pone.0172031.

Kintsler, S. *et al.* (2019) ‘Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling’, *Annals of Diagnostic Pathology*, 41, pp. 24–37. doi: 10.1016/j.anndiagpath.2019.05.005.

Ko, K. *et al.* (2017) ‘Significance of Ki-67 in non-muscle invasive bladder cancer patients: A systematic review and meta-analysis’, *Oncotarget*, 8(59), pp. 100614–100630. doi: 10.18632/oncotarget.21899.

Li, X. D. *et al.* (2019) ‘Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy’, *Annals of Surgical Oncology*, 26(12), pp. 4148–4156. doi: 10.1245/s10434-019-07529-y.

Liakou, C. I. *et al.* (2007) ‘Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer’, *Cancer Immunity*, 7(June), pp. 2–7.

Liu, Y., Bui, M. M. and Xu, B. (2017) ‘Urothelial carcinoma with squamous differentiation is associated with high tumor stage and pelvic lymph-node metastasis’, *Cancer Control*, 24(1), pp. 78–82. doi: 10.1177/107327481702400113.

Lopez-Beltran, A. *et al.* (2021) ‘Immune checkpoint inhibitors in urothelial carcinoma: Recommendations for practical approaches to pd-11 and other potential predictive biomarker testing’, *Cancers*, 13(6), pp. 1–18. doi: 10.3390/cancers13061424.

Magers, M. J. *et al.* (2019) ‘Staging of bladder cancer’, *Histopathology*, 74(1), pp. 112–134. doi: 10.1111/his.13734.

Menon, S. S. *et al.* (2019) ‘Ki-67 protein as a tumour proliferation marker’, *Clinica*

Chimica Acta, 491(November 2018), pp. 39–45. doi:
10.1016/j.cca.2019.01.011.

Moch, H. *et al.* (2016) ‘The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours’, *European Urology*, 70(1), pp. 93–105. doi:
10.1016/j.eururo.2016.02.029.

Murakami, Y. *et al.* (2020) ‘PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy’, *Urologic Oncology: Seminars and Original Investigations*, 000, pp. 1–9. doi:
10.1016/j.urolonc.2020.09.034.

Nakanishi, J. *et al.* (2007) ‘Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers’, *Cancer Immunology, Immunotherapy*, 56(8), pp. 1173–1182. doi: 10.1007/s00262-006-0266-z.

Patel, V. G., Oh, W. K. and Galsky, M. D. (2020) ‘Treatment of muscle-invasive and advanced bladder cancer in 2020’, *CA: A Cancer Journal for Clinicians*, 70(5), pp. 404–423. doi: 10.3322/caac.21631.

‘PD-L1 IHC 22C3 pharmDx Interpretation Manual – Urothelial Carcinoma’ (no date).

Pelekanou, V. *et al.* (2017) ‘Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance’, pp. 1–11. doi: 10.1186/s13058-017-0884-8.

Pichler, R. *et al.* (2017) ‘PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy Patient characteristics’, *Impactjournal*, pp. 1–16.

Prasetya, G. R. *et al.* (2019) ‘Pratista Patologi Jalur PD-1 / PD-L1 pada Clear Cell Renal Carcinoma Pratista Patologi’, 6(3).

Rouanne, M. *et al.* (2019) ‘ScienceDirect Stromal lymphocyte infiltration is

- associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer’, 108, pp. 111–119. doi: 10.1016/j.ejca.2018.12.010.
- Rubino, S. *et al.* (2020) ‘Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study’, *World Journal of Urology*, (0123456789). doi: 10.1007/s00345-020-03342-5.
- Song, D. *et al.* (2019) ‘Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches’, *Journal of Pathology*, 249(2), pp. 151–165. doi: 10.1002/path.5306.
- Sun, X. and Kaufman, P. D. (2018) ‘Ki-67: more than a proliferation marker’, *Chromosoma*, 127(2), pp. 175–186. doi: 10.1007/s00412-018-0659-8.
- Sung, H. *et al.* (2021) ‘Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, 0(0), pp. 1–41. doi: 10.3322/caac.21660.
- Syafa’ah, A., Maulani, H. and Suciati, T. (2015) ‘Angka Kejadian Karsinoma Urothelial di Bagian Patologi Anatomi RSUP Dr. Mohammad Hoesin Palembang Periode Tahun 2009-2013’, *Majalah Kedokteran Sriwijaya*, 47(1), pp. 10–16.
- Thompson, D. B. *et al.* (2015) ‘Immunological basis in the pathogenesis and treatment of bladder cancer’, *Expert Review of Clinical Immunology*, 11(2), pp. 265–279. doi: 10.1586/1744666X.2015.983082.
- Tumeh, P. C. *et al.* (2015) ‘Immune Resistance’, *Nature*, 515(7528), pp. 568–571. doi: 10.1038/nature13954.PD-1.
- Umbas, R. *et al.* (2014) *Panduan Penanganan Kanker Kandung Kemih Tipe Urothelial, Ikatan Ahli Urologi Indonesia (IAUI)*.
- Wang, L. *et al.* (2013) ‘Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification’, *Journal of B.U.ON.*, 18(2), pp. 420–424.
- Wang, Y. *et al.* (2009) ‘Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance’, *Journal of Huazhong*

University of Science and Technology - Medical Science, 29(1), pp. 77–79.
doi: 10.1007/s11596-009-0116-2.

Widayanti, L. A. *et al.* (2020) ‘Hubungan antara Tumor Infiltrating Lymphocytes (TIL), sel tumor dan TIL dengan kedalaman invasi pada karsinoma urotelial kandung kemih tipe tidak spesifik di RSUP Sanglah, Bali, Indonesia’, 11(3), pp. 738–744. doi: 10.15562/ism.v11i3.806.

Widiana, I. G. T. E. T., Suryawisesa, I. B. M. and Widiana, I. K. (2020) ‘Hubungan Ekspresi Tumor Infiltrating Lymphocytes dengan Klinikopatologi pada Subtipe Luminal A dan Triple Negative Kanker Payudara di Bali’, *JBN (Jurnal Bedah Nasional)*, 4(2), p. 43. doi: 10.24843/jbn.2020.v04.i02.p02.

Xylinas, E. *et al.* (2014) ‘Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.’, *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*, 40(1), pp. 121–127. doi: 10.1016/j.ejso.2013.08.023.

Yang, G. *et al.* (2015) ‘蚊子网状进化HHS Public Access’, 344(6188), pp. 1173–1178. doi: 10.1126/science.1249098.Sleep.

Zhao, M., He, X. L. and Teng, X. D. (2016) ‘Understanding the molecular pathogenesis and prognostics of bladder cancer: An overview’, *Chinese Journal of Cancer Research*, 28(1), pp. 92–98. doi: 10.3978/j.issn.1000-9604.2016.02.05.



UNIVERSITAS
GADJAH MADA

HUBUNGAN EKSPRESI PD-L1 DENGAN GRADING TUMOR, INDEKS PROLIFERASI, DAN TUMOR-INFLTRATING LYMPHOCYTES (TILs) PADA KARSINOMA UROTELIAL KANDUNG KEMIH

TH. HENING DWI A, dr. Hanggoro Tri Rinonce, Sp.PA(K), Ph.D; dr. Paranita Ferronika, Sp.PA(K),Ph.D
Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>